With as much as two-thirds of retail pharmacy operators' business tied up in the potential Express Scripts-Medco merger, the National Association of Chain Drug Stores, the National Community Pharmacists Association and nine retail pharmacy companies on Thursday filed a lawsuit challenging the merger.
Powerful pharmacy benefit manager Medco Health Solutions has just unveiled the results of a large-scale study that points out the critical role that pharmacist interventions play in the health and safety of women.
The National Association of Chain Drug Stores is praising lawmakers in Medco Health Solutions’ home state of New Jersey for delivering what NACDS called “a bold and revealing blow” to the PBM’s proposed merger with Express Scripts.
Pills for treating cancer have created numerous alternatives to spending hours in a clinic or at home receiving chemotherapy infusions, but risks of drug interactions remain, according to a new survey by the research arm of pharmacy benefit manager Medco Health Solutions.
Comments made by Express Scripts president and CEO George Paz after the pharmacy benefit manager's earnings call last week has garnered some attention from a coalition that is looking to stop the merger between ESI and fellow PBM Medco Health Solutions.
Multibillion-dollar pharmacy benefit management companies are advertising aggressively to try to convince Congress and the Federal Trade Commission to approve a merger between Express Scripts and Medco Health Solutions
Multibillion-dollar pharmacy benefit management companies are advertising aggressively to try to convince Congress and the Federal Trade Commission to approve a merger between Express Scripts and Medco Health Solution.
Bloomberg on Friday reported that Express Scripts intends to inform the Federal Trade Commission that the company has delivered all the data requested regarding its purchase of Medco Health Solutions on Friday, which will trigger a 30-day period for a decision from the FTC.
Will the merger of Express Scripts and Medco go through? Not if pharmacy lobbyists can stop it. There’s nothing new about the fact that different industry groups connected with retail pharmacy or health care can hold strongly opposing views about what’s good or profitable for their own members. But for undisguised hostility and tit-for-tat charges and countercharges, nothing comes close to the long-running feud between independent pharmacy and the pharmacy benefits management industry.
As we welcome a new year, it is exciting to see all the changes headed our way. With all the movement around healthcare reform and technology, we in the pharmacy industry are quick to point out that this industry is years ahead of the rest of health care in terms of payment solutions and automated workflow. The rest of the industry is running to catch up — but right now the pharmacy industry is far from where we need to be to address critical factors in our industry. That said, there are tremendous opportunities that several companies are bringing forward with new technology that can truly revolutionize the delivery of health care.
In the wake of a key Senate subcommittee hearing this month, and on the heels of the collapse of the blockbuster AT&T and T-Mobile merger, four more U.S. lawmakers have joined the growing ranks of consumer groups, members of Congress and employers questioning the proposed mega-merger of pharmacy benefit managers Express Scripts and Medco Health Solutions.
Preserve Community Pharmacy Access Now — a coalition of consumers, businesses and community-based pharmacists banded together for the purpose of opposing the planned merger between Express Scripts and Medco Health Solutions — on Thursday responded to testimony provided by George Paz, Express Scripts CEO, before the Senate Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights hearing held Tuesday.
George Paz, Express Scripts chairman and CEO, and David Snow, Medco Health Solutions chairman and CEO, were in a pair of hot seats Tuesday afternoon before the Senate Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights.
With annual sales gaining on the $8 billion mark in the United States alone, according to IMS Health, Lipitor (atorvastatin) is the top-selling drug in the world, and the price markdown that Ranbaxy Labs’ launch (and subsequent generic launches) will bring, greatly will expand its accessibility. So it’s no surprise that it has attracted so much media attention over the past few weeks.
The merger between pharmacy benefit managers Express Scripts and Medco Health Solutions "could bring an end to community-based pharmacies and the convenient services provided there," according to the Pennsylvania Pharmacy Council.
At a press conference organized by the Preserve Community Pharmacy Access NOW! coalition at the Capitol on Thursday morning, the National Community Pharmacists Association's CEO Douglas Hoey issued a statement regarding the proposed merger of pharmacy benefit managers Express Scripts and Medco Health Solutions, saying the deal could mean "more wasteful mail-order spending and higher price spikes for specialty drugs."
The Preserve Community Pharmacy Access NOW! coalition will be traveling to the nation's capital on Thursday to urge Congress and the Federal Trade Commission to support patient care and oppose the planned merger between Express Scripts and Medco Health Solutions, the coalition announced Monday.
The Preserve Community Pharmacy Access NOW! coalition, which is a coalition of consumers, businesses and community-based pharmacists from across the country that have come together to oppose the planned mega-merger of Express Scripts and Medco Health Solutions, has issued a call to action to protect Americans from rising costs and decreased access to health care by stopping the planned merger of the PBMs.
A number of members of Congress have raised questions about the proposed merger between pharmacy benefit managers Express Scripts and Medco Health Solutions, prompting a lobbying group that represents independent pharmacies and opposes the merger to highlight the matter.